Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Oncologic and Triton BioSystems Merge to Form Aduro BioTech: Aduro to Focus on NT™ and TNT™ Systems for Solid Tumor Cancers

Abstract:
Two early stage cancer therapy companies, Oncologic and Triton BioSystems, have merged to create Aduro BioTech. Aduro, which is privately held, will be headquartered at the former Oncologic facility in Berkeley, California.

Oncologic and Triton BioSystems Merge to Form Aduro BioTech: Aduro to Focus on NT™ and TNT™ Systems for Solid Tumor Cancers

Berkeley, CA | Posted on June 2nd, 2008

Aduro will focus on the development of its proprietary and minimally invasive NT™ and TNT™ cancer therapies, which use patented iron oxide nano-particles to target and kill solid tumor cancers. The nano-particles are engineered to efficiently generate high levels of heat when exposed to an externally applied magnetic field, and this heat kills tumor cells without the toxicity or collateral damage that result from traditional chemotherapy or radiation treatments.

"There are several exciting aspects of the Aduro technology that we believe can offer significant improvements to current therapies," said Stephen T. Isaacs, CEO of Aduro. "We are developing a cancer therapy based on the low toxicity of iron oxide, which is an innocuous material currently used in a variety of medical applications. If successfully developed, the Aduro products will be an exceedingly important addition to the field of solid tumor cancer therapy."

According to the company, one of the major problems with current cancer therapy is the collateral damage to normal tissues, and that it's often not the failure of radiation or chemotherapeutic agent to kill the tumor that's the problem, but rather the inability to deliver a "knock-out" punch because of dose-limiting toxicity. The company believes that unlike radiation or chemotherapy, the Aduro NT™ and TNT™ particles will be innocuous until activation by an external (non-invasive) alternating magnetic field. Due to the low-toxicity of iron oxide and the targeting agents which guide the nano-particles to the tumor, Aduro believes its NT™ and TNT™ therapeutic products may be used at higher dose levels than current therapies, which in turn should provide significantly improved therapeutic outcomes.

Oncologic and Triton BioSystems Merge to Form Aduro BioTech

Mr. Isaacs said that the technology has been demonstrated to work in a murine (mouse) system with both direct and systemic infusions of the NT™ and TNT™ nano-particles. "We believe the NT™ (direct infusion) method is the shortest path to the clinic, and we hope to start a clinical trial for accessible head and neck cancer in 2009," Mr. Isaacs continued. "Our basic strategy is to be first to show direct clinical benefit with ‘thermal therapy' in humans, then to move on the more interesting systemic approach with the TNT™ method, which we believe holds promise for metastatic disease."

In 1991, Mr. Isaacs founded Cerus Corporation (NASD: CERS), where he served as CEO for fourteen years. During Isaacs' tenure, Cerus became a publicly traded company, entered several major corporate partnerships, raised over 250 million dollars, and brought its first product to market in Europe. He is joined by several seasoned cancer researchers, including Drs. Paul Chinn and Gary Braslawsky, who worked together at Biogen-Idec, where they led the development of Zevalin®, an FDA-approved radio-pharmaceutical used for the treatment of non-Hodgkin's lymphoma (a blood cancer).

Aduro BioTech simultaneously closed on its Series A financing round, which included a consortium of insiders and new investors. Terms of the financing were not disclosed.

© 2008 Aduro BioTech, Inc. TNT™ and NT™ are trademarks of Aduro; Zevalin®is a registered trademark of Cell Therapeutics, Inc.

####

For more information, please click here

Contacts:
Aduro BioTech
David S. Rose
510-848-4400 x101

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Scientists reveal breakthrough in optical fiber communications December 21st, 2014

Atom-thick CCD could capture images: Rice University scientists develop two-dimensional, light-sensitive material December 20th, 2014

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Pixelligent Closes $5.5 Million in Funding: Capital Will Be Used to Support Global Customer Growth December 12th, 2014

Eight19 secures £1m funding: Investment to develop production technology, and expand commercial activities for organic photovoltaics November 19th, 2014

Harris & Harris Group Reports Financial Statements as of September 30, 2014 November 11th, 2014

Harris & Harris Group to Host Conference Call on Third Quarter 2014 Financial Results on November 12, 2014 November 3rd, 2014

Nanomedicine

Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014

Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014

Unraveling the light of fireflies December 17th, 2014

First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014

Announcements

Scientists reveal breakthrough in optical fiber communications December 21st, 2014

Atom-thick CCD could capture images: Rice University scientists develop two-dimensional, light-sensitive material December 20th, 2014

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

Acquisitions/Mergers/Splits

Keysight Technologies Begins Trading as Independent Company November 3rd, 2014

PEN Inc. Chairman, Scott Rickert, Will Webcast a Live Company Update September 25, 1 PM EDT September 17th, 2014

State University of New York Trustees Unanimously Approve SUNY Polytechnic Institute (SUNY Poly) as New Name for Merged SUNY CNSE / SUNYIT September 9th, 2014

PEN Inc. Announces New Trading Symbol: PENC: Stock Continues Trading on the OTCQB September 3rd, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE